Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.08
TEVA's Cash to Debt is ranked lower than
91% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. TEVA: 0.08 )
Ranked among companies with meaningful Cash to Debt only.
TEVA' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.31 Max: N/A
Current: 0.08
Equity to Asset 0.47
TEVA's Equity to Asset is ranked lower than
72% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. TEVA: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
TEVA' s Equity to Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.50 Max: 0.6
Current: 0.47
0.39
0.6
F-Score: 4
Z-Score: 2.19
M-Score: -2.67
WACC vs ROIC
5.38%
8.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 21.93
TEVA's Operating margin (%) is ranked higher than
85% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.51 vs. TEVA: 21.93 )
Ranked among companies with meaningful Operating margin (%) only.
TEVA' s Operating margin (%) Range Over the Past 10 Years
Min: 8.12  Med: 17.14 Max: 25.46
Current: 21.93
8.12
25.46
Net-margin (%) 8.90
TEVA's Net-margin (%) is ranked higher than
60% of the 684 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.44 vs. TEVA: 8.90 )
Ranked among companies with meaningful Net-margin (%) only.
TEVA' s Net-margin (%) Range Over the Past 10 Years
Min: 5.73  Med: 14.73 Max: 20.75
Current: 8.9
5.73
20.75
ROE (%) 7.69
TEVA's ROE (%) is ranked higher than
52% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. TEVA: 7.69 )
Ranked among companies with meaningful ROE (%) only.
TEVA' s ROE (%) Range Over the Past 10 Years
Min: 4.23  Med: 11.88 Max: 18.76
Current: 7.69
4.23
18.76
ROA (%) 3.71
TEVA's ROA (%) is ranked higher than
50% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. TEVA: 3.71 )
Ranked among companies with meaningful ROA (%) only.
TEVA' s ROA (%) Range Over the Past 10 Years
Min: 2.26  Med: 6.13 Max: 10.71
Current: 3.71
2.26
10.71
ROC (Joel Greenblatt) (%) 55.14
TEVA's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.81 vs. TEVA: 55.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TEVA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 16.41  Med: 33.56 Max: 49.79
Current: 55.14
16.41
49.79
Revenue Growth (3Y)(%) 4.80
TEVA's Revenue Growth (3Y)(%) is ranked lower than
53% of the 581 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. TEVA: 4.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TEVA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.8  Med: 16.55 Max: 23.4
Current: 4.8
4.8
23.4
EBITDA Growth (3Y)(%) 10.70
TEVA's EBITDA Growth (3Y)(%) is ranked higher than
56% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. TEVA: 10.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TEVA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.5  Med: 16.05 Max: 47.2
Current: 10.7
-10.5
47.2
EPS Growth (3Y)(%) 4.80
TEVA's EPS Growth (3Y)(%) is ranked lower than
51% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. TEVA: 4.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TEVA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.5  Med: 16.00 Max: 69.5
Current: 4.8
-25.5
69.5
» TEVA's 10-Y Financials

Financials (Next Earnings Date: 2016-02-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

TEVA Guru Trades in Q1 2015

Andreas Halvorsen 228,600 sh (New)
Stanley Druckenmiller 790,500 sh (New)
Paul Tudor Jones 550,000 sh (New)
First Eagle Investment 4,205,481 sh (+71.77%)
Jim Simons 1,338,963 sh (+38.80%)
Pioneer Investments 1,147,578 sh (+10.80%)
Manning & Napier Advisors, Inc 311,423 sh (+6.26%)
Ronald Muhlenkamp 176,710 sh (+0.18%)
Bernard Horn 65,600 sh (unchged)
Charles Brandes 3,600 sh (unchged)
Caxton Associates Sold Out
Louis Moore Bacon Sold Out
George Soros Sold Out
Michael Price 440,300 sh (-1.61%)
Richard Snow 1,807,419 sh (-2.66%)
John Keeley 36,835 sh (-2.95%)
James Barrow 10,189,904 sh (-5.85%)
NWQ Managers 3,669,079 sh (-8.53%)
Diamond Hill Capital 199,641 sh (-15.12%)
David Dreman 100,133 sh (-16.44%)
Vanguard Health Care Fund 1,896,960 sh (-61.47%)
Steven Cohen 91,000 sh (-61.76%)
» More
Q2 2015

TEVA Guru Trades in Q2 2015

George Soros 423,308 sh (New)
Larry Robbins 2,844,400 sh (New)
John Paulson 2,030,500 sh (New)
Steven Cohen 179,500 sh (+97.25%)
Jim Simons 2,075,763 sh (+55.03%)
Manning & Napier Advisors, Inc 336,513 sh (+8.06%)
Pioneer Investments 1,155,466 sh (+0.69%)
Ronald Muhlenkamp 176,915 sh (+0.12%)
Bernard Horn 65,600 sh (unchged)
Michael Price 440,300 sh (unchged)
Andreas Halvorsen Sold Out
Vanguard Health Care Fund Sold Out
Stanley Druckenmiller Sold Out
Charles Brandes Sold Out
John Keeley 36,280 sh (-1.51%)
James Barrow 9,862,843 sh (-3.21%)
David Dreman 90,345 sh (-9.77%)
First Eagle Investment 3,756,998 sh (-10.66%)
Richard Snow 1,603,308 sh (-11.29%)
NWQ Managers 2,984,606 sh (-18.66%)
Paul Tudor Jones 400,000 sh (-27.27%)
Diamond Hill Capital 138,189 sh (-30.78%)
» More
Q3 2015

TEVA Guru Trades in Q3 2015

Andreas Halvorsen 8,872,650 sh (New)
John Paulson 18,000,000 sh (+786.48%)
Steven Cohen 373,800 sh (+108.25%)
Larry Robbins 4,188,779 sh (+47.26%)
Pioneer Investments 1,639,229 sh (+41.87%)
Jim Simons 2,878,763 sh (+38.68%)
First Eagle Investment 4,467,011 sh (+18.90%)
Ronald Muhlenkamp 176,955 sh (+0.02%)
Manning & Napier Advisors, Inc 336,513 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Michael Price 440,300 sh (unchged)
George Soros Sold Out
Manning & Napier Advisors, Inc 335,793 sh (-0.21%)
John Keeley 35,990 sh (-0.80%)
James Barrow 9,522,401 sh (-3.45%)
Richard Snow 1,377,992 sh (-14.05%)
NWQ Managers 2,408,826 sh (-19.29%)
David Dreman 42,892 sh (-52.52%)
Diamond Hill Capital 11,525 sh (-91.66%)
Paul Tudor Jones 10,300 sh (-97.43%)
» More
Q4 2015

TEVA Guru Trades in Q4 2015

Vanguard Health Care Fund 5,800,000 sh (New)
James Barrow 9,602,463 sh (+0.84%)
» More
» Details

Insider Trades

Latest Guru Trades with TEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Teva Pharmaceutical Industries Ltd

Vanguard Health Care Fund Comments on Teva Pharmaceutical Industries Ltd - Mar 27, 2015

We trimmed into strength our position in Teva (TEVA), an Israel-based global biopharmaceutical company specializing in generic formulations. The stock rose substantially on a combination of speculation around M&A in the sector, enthusiasm for the new CEO, and the strong conversion of once-daily Copaxone to the three-times-a-week version.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Diamond Hill Capital Comments on Teva Pharmaceutical Industries Ltd - Jun 26, 2014

Generic drug manufacturer Teva Pharmaceutical Industries Ltd. (TEVA) benefitted from the addition of a well-respected CEO and the continued successful transition of patients to a new, patent-protected version of the company’s multiple sclerosis drug.



From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

NWQ Managers Reduces Stakes in Microsoft, MetLife and Teva Pharmaceutical Company cuts 3 stakes by more than 43%
NWQ Managers (Trades, Portfolio) reduced several of its stakes in the third quarter, some by more than 43%. Read more...
John Paulson Increases Holding in Teva Pharmaceutical A look at the hedge fund manager's recent trades
John Paulson is an American hedge fund manager and billionaire who founded the New York-based investment management firm Paulson & Co. in 1994. Paulson has most recently added 18,000,000 shares of Teva Pharmaceutical Industries (NYSE:TEVA), a 746.48% increase in his holding. Paulson & Co. have also bought 2,938,500 shares of Perrigo Co. PLC (NYSE:PRGO) and 7,007,346 shares of CIT Group Inc. (NYSE:CIT). Read more...
Ronald Muhlenkamp's Highest-Yielding Stocks JPMorgan and Teva Pharmaceutical top the list
Ronald Muhlenkamp is the founder and president of Muhlenkamp & Company Inc. and the portfolio manager for the company's mutual fund. His portfolio is composed of 64 stocks with a total value of $340 million. The following are the stocks in his portfolio with the highest growing yield. Read more...
Hedge Fund Menta Capital's Top Stocks Include Teva Pharmaceutical, NICE Systems Menta increased its stake in Teva by 41%
Hedge fund Menta Capital disclosed an equity portfolio valued at $612.3 million as of the end of the second quarter of 2015. The equity portfolio is mainly invested in finance (20%), technology (19%) and consumer discretionary (14%) stocks.  Read more...
Paul Tudor Jones Buys Stakes in ADP and Visa
Paul Tudor Jones (Trades, Portfolio), founder of Tudor Investment Corporation, has been estimated to be worth in excess of $4 billion. Much of his money was made when he predicted “Black Monday” in October 1987, thanks to large short positions. Read more...
Vanguard Health Care Fund Comments on Teva Pharmaceutical Industries Ltd
We trimmed into strength our position in Teva (TEVA), an Israel-based global biopharmaceutical company specializing in generic formulations. The stock rose substantially on a combination of speculation around M&A in the sector, enthusiasm for the new CEO, and the strong conversion of once-daily Copaxone to the three-times-a-week version. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 28.50
TEVA's P/E(ttm) is ranked lower than
53% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.86 vs. TEVA: 28.50 )
Ranked among companies with meaningful P/E(ttm) only.
TEVA' s P/E(ttm) Range Over the Past 10 Years
Min: 10.53  Med: 20.47 Max: 1072.29
Current: 28.5
10.53
1072.29
Forward P/E 10.13
TEVA's Forward P/E is ranked higher than
82% of the 419 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.50 vs. TEVA: 10.13 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.40
TEVA's PE(NRI) is ranked higher than
50% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.45 vs. TEVA: 28.40 )
Ranked among companies with meaningful PE(NRI) only.
TEVA' s PE(NRI) Range Over the Past 10 Years
Min: 10.53  Med: 20.57 Max: 938.25
Current: 28.4
10.53
938.25
P/B 2.21
TEVA's P/B is ranked higher than
59% of the 928 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.54 vs. TEVA: 2.21 )
Ranked among companies with meaningful P/B only.
TEVA' s P/B Range Over the Past 10 Years
Min: 1.37  Med: 2.31 Max: 4.81
Current: 2.21
1.37
4.81
P/S 2.54
TEVA's P/S is ranked higher than
51% of the 929 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.60 vs. TEVA: 2.54 )
Ranked among companies with meaningful P/S only.
TEVA' s P/S Range Over the Past 10 Years
Min: 1.58  Med: 3.09 Max: 5.86
Current: 2.54
1.58
5.86
PFCF 14.46
TEVA's PFCF is ranked higher than
80% of the 485 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.85 vs. TEVA: 14.46 )
Ranked among companies with meaningful PFCF only.
TEVA' s PFCF Range Over the Past 10 Years
Min: 8.45  Med: 16.44 Max: 32.92
Current: 14.46
8.45
32.92
POCF 8.92
TEVA's POCF is ranked higher than
86% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.68 vs. TEVA: 8.92 )
Ranked among companies with meaningful POCF only.
TEVA' s POCF Range Over the Past 10 Years
Min: 6.56  Med: 12.18 Max: 23.31
Current: 8.92
6.56
23.31
EV-to-EBIT 14.00
TEVA's EV-to-EBIT is ranked higher than
69% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.42 vs. TEVA: 14.00 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 12  Med: 19.10 Max: 991
Current: 14
12
991
EV-to-EBITDA 12.10
TEVA's EV-to-EBITDA is ranked higher than
67% of the 852 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. TEVA: 12.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.1  Med: 15.20 Max: 290.6
Current: 12.1
9.1
290.6
PEG 6.04
TEVA's PEG is ranked lower than
78% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. TEVA: 6.04 )
Ranked among companies with meaningful PEG only.
TEVA' s PEG Range Over the Past 10 Years
Min: 0.35  Med: 1.49 Max: 135.59
Current: 6.04
0.35
135.59
Shiller P/E 25.60
TEVA's Shiller P/E is ranked higher than
73% of the 166 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.90 vs. TEVA: 25.60 )
Ranked among companies with meaningful Shiller P/E only.
TEVA' s Shiller P/E Range Over the Past 10 Years
Min: 18.72  Med: 34.09 Max: 101.16
Current: 25.6
18.72
101.16
Current Ratio 0.96
TEVA's Current Ratio is ranked lower than
89% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. TEVA: 0.96 )
Ranked among companies with meaningful Current Ratio only.
TEVA' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.59 Max: 2.95
Current: 0.96
0.92
2.95
Quick Ratio 0.65
TEVA's Quick Ratio is ranked lower than
88% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. TEVA: 0.65 )
Ranked among companies with meaningful Quick Ratio only.
TEVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.08 Max: 2.19
Current: 0.65
0.63
2.19
Days Inventory 183.37
TEVA's Days Inventory is ranked lower than
77% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 119.42 vs. TEVA: 183.37 )
Ranked among companies with meaningful Days Inventory only.
TEVA' s Days Inventory Range Over the Past 10 Years
Min: 131.65  Med: 186.40 Max: 208.14
Current: 183.37
131.65
208.14
Days Sales Outstanding 96.56
TEVA's Days Sales Outstanding is ranked lower than
65% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.67 vs. TEVA: 96.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 96.56
95.91
153.21

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.31
TEVA's Dividend Yield is ranked higher than
70% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.43 vs. TEVA: 2.31 )
Ranked among companies with meaningful Dividend Yield only.
TEVA' s Dividend Yield Range Over the Past 10 Years
Min: 0.46  Med: 1.15 Max: 3.26
Current: 2.31
0.46
3.26
Dividend Payout 0.65
TEVA's Dividend Payout is ranked lower than
78% of the 418 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. TEVA: 0.65 )
Ranked among companies with meaningful Dividend Payout only.
TEVA' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.13 Max: 5
Current: 0.65
0.04
5
Dividend Growth (3y) 15.30
TEVA's Dividend Growth (3y) is ranked higher than
70% of the 279 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. TEVA: 15.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
TEVA' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -6.7  Med: 27.85 Max: 80.9
Current: 15.3
-6.7
80.9
Forward Dividend Yield 2.31
TEVA's Forward Dividend Yield is ranked higher than
67% of the 614 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.56 vs. TEVA: 2.31 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 6.61
TEVA's Yield on cost (5-Year) is ranked higher than
91% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.79 vs. TEVA: 6.61 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TEVA' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.31  Med: 3.26 Max: 9.25
Current: 6.61
1.31
9.25
3-Year Average Share Buyback Ratio 1.30
TEVA's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 458 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.90 vs. TEVA: 1.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.9  Med: -3.70 Max: 2.6
Current: 1.3
-10.9
2.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.03
TEVA's Price/Projected FCF is ranked higher than
88% of the 523 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. TEVA: 1.03 )
Ranked among companies with meaningful Price/Projected FCF only.
TEVA' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.6  Med: 1.49 Max: 29.19
Current: 1.03
0.6
29.19
Price/DCF (Earnings Based) 1.38
TEVA's Price/DCF (Earnings Based) is ranked higher than
79% of the 124 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.55 vs. TEVA: 1.38 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.82
TEVA's Price/Median PS Value is ranked higher than
81% of the 899 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. TEVA: 0.82 )
Ranked among companies with meaningful Price/Median PS Value only.
TEVA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.52  Med: 1.10 Max: 1.89
Current: 0.82
0.52
1.89
Price/Peter Lynch Fair Value 5.18
TEVA's Price/Peter Lynch Fair Value is ranked lower than
89% of the 244 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.72 vs. TEVA: 5.18 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
TEVA' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.54  Med: 1.44 Max: 112.82
Current: 5.18
0.54
112.82
Earnings Yield (Greenblatt) (%) 7.10
TEVA's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 720 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. TEVA: 7.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TEVA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 5.20 Max: 8.4
Current: 7.1
0.1
8.4
Forward Rate of Return (Yacktman) (%) 11.76
TEVA's Forward Rate of Return (Yacktman) (%) is ranked higher than
62% of the 318 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.62 vs. TEVA: 11.76 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TEVA' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 9.2  Med: 19.20 Max: 46.2
Current: 11.76
9.2
46.2

More Statistics

Revenue(Mil) $19939
EPS $ 2.07
Beta0.55
Short Percentage of Float1.88%
52-Week Range $54.17 - 72.31
Shares Outstanding(Mil)852.00

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 19,583 24,324 24,364 25,710
EPS($) 5.30 5.63 5.81 7.15
EPS without NRI($) 5.30 5.63 5.81 7.15

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, AGN, FRX, MRX, ESALF » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVJF.USA,
Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments such as generic products, which includes chemical and therapeutic equivalents of originator pharmaceuticals in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants, as well as API business; and specialty products, which includes several core franchises, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines, as well as other areas such as oncology and women's health. In addition to these two segments, the Company has other activities, primarily PGT Healthcare, OTC joint venture with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices. The Company, along with its subsidiaries operates in approximately 60 countries. It develops, manufactures and sell generic pharmaceutical products in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. Specialty medicines business, which is focused on delivering solutions to patients and providers via medicines, devices and services in all key regions and markets around the world, includes several core therapeutic areas, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines. Some of its products are Copaxone, Azilect & Provigil, among others. The Company markets approximately 375 generic products in more than 1,100 dosage strengths and packaging sizes, including oral, injectables and inhaled products. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").
» More Articles for TEVA

Headlines

Articles On GuruFocus.com
NWQ Managers Reduces Stakes in Microsoft, MetLife and Teva Pharmaceutical Dec 23 2015 
Halvorsen's Investment Makes Broadcom His Fifth-Most Valuable Stake Dec 05 2015 
John Paulson Increases Holding in Teva Pharmaceutical Nov 17 2015 
KEELEY All Cap Value Fund Q3 2015 Manager Commentary Nov 03 2015 
Hedge Fund Menta Capital's Top Stocks Include Teva Pharmaceutical, NICE Systems Sep 09 2015 
Daniel Loeb's Third Point Second Quarter Investor Letter Aug 03 2015 
Weekly 52-Week Highs Highlight: GIS, AAP, BCR, TEVA Jul 28 2015 
Paul Tudor Jones Buys Stakes in ADP and Visa Jun 19 2015 
KEELEY All Cap Value Fund First Quarter 2015 Commentary Jun 17 2015 
Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks Jun 11 2015 

More From Other Websites
Factors of Influence in Today's Market - Analyst Notes on Hess, Teva Pharmaceutical Industries,... Feb 05 2016
The 4 'Momentum Triggers' That Could Give This Biotech Stock 64% Growth Feb 02 2016
Teva Shareholders Shrug Off Latest Collaborative Research Agreement Feb 02 2016
Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies Feb 02 2016
Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies Feb 02 2016
U.S. appeals court ruling may clear barrier to generic OxyContin Feb 01 2016
How Much Is Teva Spending on Research and Development? Jan 29 2016
Antitrust Watchdog: Usual Merger Fix Won't Help Teva's Allergan Deal Jan 29 2016
Insight into Teva’s Over-the-Counter and Distribution Businesses Jan 28 2016
Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKA™ (bendamustine... Jan 28 2016
Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKA™ (bendamustine... Jan 28 2016
Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKA™ (bendamustine... Jan 28 2016
Short Sellers Become More Selective on Major Pharma Jan 28 2016
Teva to Report Fourth Quarter 2015 Financial Results on February 11, 2016 Jan 28 2016
Teva to Report Fourth Quarter 2015 Financial Results on February 11, 2016 Jan 28 2016
Teva Releases Innovation and Social Responsibility Highlights Jan 25 2016
Teva Releases Innovation and Social Responsibility Highlights Jan 25 2016
How Will Teva Finance the Actavis Acquisition? Jan 21 2016
Teva’s Debt Position and Valuations Jan 19 2016
United Therapeutics settles patent dispute with Teva Pharmaceuticals Jan 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK